Phase 1 · Irvine, CA
Phase 1 clinical trials in Irvine, CA
6 recruiting studies have a site in Irvine.
6 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingHealthy volunteersPhase 1
A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD)
Bambusa Therapeutics
- Location
- Irvine, CA + 2 other US sites
- Eligibility basics
- Ages 18–72
- RecruitingPhase 1/Phase 2
A Study to Evaluate Safety, Tolerability, and Efficacy of AB-1009 Gene Therapy (GAA Gene) in Adult Participants With Late-Onset Pompe Disease (PROGRESS-GT LOPD)
AskBio Inc
- Location
- Irvine, CA + 4 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 1/Phase 2
A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease
AbbVie
- Location
- Irvine, CA + 10 other US sites
- Eligibility basics
- Ages 50–90
- RecruitingPhase 1
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of DNL952 in Adult Participants With Late-Onset Pompe Disease
Denali Therapeutics Inc.
- Location
- Irvine, CA + 3 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 1/Phase 2
A Study Exploring Changes in a Variety of Biomarkers Following Dosing With MT1988 in Participants at Clinical High Risk for Psychosis
Monument Therapeutics Limited
- Location
- Irvine, CA + 14 other US sites
- Eligibility basics
- Ages 17–30
- RecruitingPhase 1
A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
Fate Therapeutics
- Location
- Irvine, CA + 15 other US sites
- Eligibility basics
- Ages 12–70
Who these studies look for
Phase 1 studies often have narrow eligibility: specific age and weight ranges, no recent participation in another study, no nicotine, and limits on medications. Some Phase 1 studies recruit patients rather than healthy volunteers, so check each listing.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.